First-line nivolumab (anti-PD-1) monotherapy in advanced NSCLC: the story of immune checkpoint inhibitors and "the sorcerers apprentice"

被引：15
|
作者：
Schmid-Bindert, Gerald [1 ]
Jiang, Tao [2 ]
机构：
[1] Heidelberg Univ, Med Fac Mannheim, Dept Surg, Mannheim, Germany
[2] Tongji Univ, Shanghai Pulm Hosp, Sch Med, Dept Oncol, Shanghai 200433, Peoples R China
来源：
TRANSLATIONAL LUNG CANCER RESEARCH | 2015年 / 4卷 / 03期
关键词：
D O I：
10.3978/j.issn.2218-6751.2015.01.12
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：215 / 216
页数：2
相关论文
共 50 条
  • [1] First-line nivolumab (anti-PD-1; BMS-936558, ONO-4538) monotherapy in advanced NSCLC: Safety, efficacy, and correlation of outcomes with PD-L1 status.
    Gettinger, Scott N.
    Shepherd, Frances A.
    Antonia, Scott Joseph
    Brahmer, Julie R.
    Chow, Laura Quan Man
    Juergens, Rosalyn A.
    Borghaei, Hossein
    Shen, Yun
    Harbison, Christopher
    Alaparthy, Suresh
    Chen, Allen C.
    Rizvi, Naiyer A.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [2] Use of First-Line Immune Checkpoint Inhibitors and Association With Overall Survival Among Patients With Metastatic Melanoma in the Anti-PD-1 Era
    Lamba, Nayan
    Ott, Patrick A.
    Iorgulescu, J. Bryan
    [J]. JAMA NETWORK OPEN, 2022, 5 (08) : E2225459
  • [3] Real-world data prognostic model of overall survival in patients with advanced NSCLC receiving anti-PD-1/PD-L1 immune checkpoint inhibitors as second-line monotherapy
    Julian, Cristina
    Machado, Robson J. M.
    Girish, Sandhya
    Chanu, Pascal
    Heinzmann, Dominik
    Harbron, Chris
    Gershon, Anda
    Pfeiffer, Shannon M.
    Zou, Wei
    Quarmby, Valerie
    Zhang, Qing
    Chen, Yachi
    [J]. CANCER REPORTS, 2022, 5 (10)
  • [4] Anti-PD-1 therapies—a new first-line option in advanced melanoma
    Ryan J. Sullivan
    Keith T. Flaherty
    [J]. Nature Reviews Clinical Oncology, 2015, 12 : 625 - 626
  • [5] Use of Different Anti-PD-1 Checkpoint Combination Strategies for First-Line Advanced NSCLC Treatment-The Experience of Ion Chiricută Oncology Institute
    Preda, Alexandra-Cristina
    Ciuleanu, Tudor-Eliade
    Todor, Nicolae
    Vlad, Catalin
    Iancu, Dana Ioana
    Mocan, Cristina
    Bandi-Vasilica, Mariana
    Albu, Florina
    Todor-Bondei, Irina Mihaela
    Hapca, Madalina Claudia
    Kubelac, Milan-Paul
    Kubelac-Varro, Adelina Dadiana
    [J]. CANCERS, 2024, 16 (11)
  • [6] Immune checkpoint inhibitors and chemotherapy in first-line NSCLC: a meta-analysis
    Petrelli, Fausto
    Ferrara, Roberto
    Signorelli, Diego
    Ghidini, Antonio
    Proto, Claudia
    Roudi, Raheleh
    Sabet, Mehrdad N.
    Facelli, Sara
    Garassino, Marina C.
    Luciani, Andrea
    Roviello, Giandomenico
    [J]. IMMUNOTHERAPY, 2021, 13 (07) : 621 - 632
  • [7] Anti-PD-1 therapies- a new first-line option in advanced melanoma
    Sullivan, Ryan J.
    Flaherty, Keith T.
    [J]. NATURE REVIEWS CLINICAL ONCOLOGY, 2015, 12 (11) : 625 - 626
  • [8] The Safety of First-line and Subsequent Monotherapy of PD-1/PD-L1 Inhibitors in NSCLC: A Meta Analysis
    Yang, Y.
    Xie, Z.
    Pang, P.
    Wang, N.
    Liang, H.
    Zhao, L.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S1048 - S1049
  • [9] First-Line Monotherapy With Nivolumab (Anti-PD-1; BMS-936558, ONO-4538) in Advanced Non-Small Cell Lung Cancer (NSCLC): Safety, Efficacy, and Correlation of Outcomes With PD-L1 Status
    Rizvi, N. A.
    Shepherd, F. A.
    Antonia, S. J.
    Brahmer, J. R.
    Chow, L. Q.
    Goldman, J.
    Juergens, R.
    Borghaei, H.
    Ready, N. E.
    Gerber, D. E.
    Shen, Y.
    Harbison, C.
    Chen, A. C.
    Gettinger, S.
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2014, 90 : S31 - S31
  • [10] Chemotherapy and/or immune checkpoint inhibitors in NSCLC first-line setting: what is the best approach?
    Della Gravara, Luigi
    Battiloro, Ciro
    Cantile, Rosa
    Letizia, Antonietta
    Vitiello, Fabiana
    Montesarchio, Vincenzo
    Rocco, Danilo
    [J]. LUNG CANCER MANAGEMENT, 2020, 9 (01)
12345